诊断专用抗体市场－全球产业规模、份额、趋势、机会及预测（按抗体、应用、最终用户、地区和竞争格局划分，2021-2031年）

全球诊断专用抗体市场预计将从 2025 年的 281.2 亿美元成长到 2031 年的 390.2 亿美元，复合年增长率为 5.61%。

这些特製的单株和多株抗体专为体外诊断检测而设计，用于识别与特定疾病状态相关的生物标记。推动这一增长的关键因素包括：全球慢性病和感染疾病发病率的上升，这促使人们需要精准的早期检测；以及依赖准确患者分层的个人化医疗的日益普及。此外，全球人口老化也持续推高了对高频诊断检测和免疫组织化学检测服务的强劲需求。

儘管有这些积极迹象，但该行业仍面临许多挑战，包括由于新型诊断剂的检验和商业化法规结构严格，导致研发週期过长。这些合规要求可能会阻碍创新解决方案的快速应用，即便临床需求迫切。美国癌症协会的数据凸显了这项需求，该协会预测，到2024年，美国将新增超过200万例癌症病例。如此沉重的疾病负担凸显了先进诊断工具的必要性，而监管的复杂性仍然是市场扩张的主要障碍。

市场驱动因素

慢性病和感染疾病的日益普及是推动全球诊断专用抗体市场成长的主要因素。在疾病负担不断加重的情况下，医疗基础设施越来越依赖基于抗体的检测方法来准确识别和监测病原体。世界卫生组织（世卫组织）于2024年10月发布的《2024年全球结核病报告》显示，2023年全球新增结核病病例约820万例，这将是自全球开始追踪结核病以来的最高数字。此外，非传染性疾病的广泛流行也使得持续的生物标记监测变得特别必要。国际糖尿病联盟的报告指出，到2024年，全球约有5.89亿成年人患有糖尿病，凸显了需要持续监测的慢性疾病规模之大。

个人化医疗和伴随诊断的进步也在推动市场扩张方面发挥关键作用。现代治疗方法，尤其是在肿瘤治疗领域，高度依赖抗体介导的检测来识别治疗前的特定生物标记物，凸显了特异性抗体在患者分层中的不可或缺性。因此，主要市场参与企业正经历持续成长。例如，根据罗氏公司于2025年1月发布的2024年年度报告，该公司诊断部门的销售额预计将增长4%，达到143亿瑞士法郎，这主要得益于对免疫诊断产品和伴随诊断的强劲需求。这项财务上的成功证实了高特异性抗体在推动精准医疗方面发挥的关键作用。

市场挑战

针对新型诊断剂的检验和商业化，严格的监管框架对全球诊断专用抗体市场的成长构成了重大障碍。世界各地的监管机构正在实施日益严格的临床证据标准，以确认体外诊断 (IVD) 测试中所用抗体的敏感度和特异性。这些合规要求需要进行全面的数据收集和漫长的临床试验，从而显着延长了研发週期并增加了资本成本。因此，製造商往往被迫将大量资源从研发转移到合规性要求上，造成瓶颈，延缓了用于检测复杂疾病状态的新型生物标记的推出。

这些营运压力阻碍了产品在法规环境复杂的地区上市，直接限制了市场扩张。核准时间的不确定性构成了进入壁垒，影响着成熟和新兴的生物技术公司，迫使它们精简产品组合或放弃小众诊断应用。 MedTech Europe 2024年的行业调查数据显示，由于监管的复杂性，选择欧盟作为主要产品上市地区的领先诊断製造商比例下降了40%，凸显了市场活动的下滑。此类策略调整和延误限制了关键诊断工具的获取，并最终限制了产业的获利潜力。

市场趋势

将人工智慧 (AI) 应用于抗体发现和设计，透过缩短筛检时间和提高结合亲和性，正在彻底改变特异性诊断抗体的开发。生成式 AI 模型现在可以预测蛋白质结构并设计具有高特异性的新型抗体序列，从而为传统的、劳动密集的动物免疫方法提供了一种替代方案。这项技术进步使得针对以往无法治疗的标靶快速生成抗体成为可能，显着加速了新型诊断检测的商业化。为了强调对 AI 驱动生物学的这项投资，2024 年 4 月 Business Wire 发布的新闻稿《Xaira Therapeutics 成立，旨在透过加速和利用 AI 在药物发现和开发中的应用，提供变革性药物》宣布，Xaira Therapeutics 已筹集超过 10 亿美元的承诺资本，旨在透过 AI 的抗体端到端应用，彻底的抗体发现过程和药物应用。

同时，即时检测（POC​​）抗体诊断技术的显着发展正推动市场去中心化，将检测流程从中心检查室转移到基层医疗机构和药房。这一趋势的驱动力源于对快速临床决策的需求，利用高亲和性抗体和小型微流体进行快速横向流动化验，可在数分钟内识别病原体和慢性病生物标记。因此，领先的诊断公司正积极收购专业技术，以增强其分散式检查能力。罗氏公司在2024年7月发布的题为「罗氏完成对LumiraDx POC技术的收购，扩大基层医疗的诊断检测覆盖范围」的新闻稿中宣布，已完成对LumiraDx POC技术的收购，交易金额为2.95亿美元，旨在加强其在全球去中心化诊断领域的业务。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章：全球诊断抗体市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依抗体类型（单株抗体、多株抗体、重组多株抗体）
  • 依应用领域（登革热诊断、爱滋病诊断、肝炎诊断、感染疾病诊断、肿瘤诊断、结核病诊断）
  • 依最终用户（诊断检查室、医院等）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美诊断专用抗体市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲诊断特殊抗体市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区诊断专用抗体市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲诊断专用抗体市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲诊断特殊抗体市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球诊断专用抗体市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• F Hoffmann-La Roche Ltd
• Abcam Limited
• Abbott Laboratories Inc
• Bio-Rad Laboratories Inc
• Agilent Technologies Inc
• Creative Diagnostics
• Thermo Fisher Scientific Inc
• Becton Dickinson & Company
• Merck KGaA
• Sartorius AG

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Diagnostic Specialty Antibodies Market is anticipated to expand from USD 28.12 Billion in 2025 to USD 39.02 Billion by 2031, reflecting a CAGR of 5.61%. These specialized monoclonal and polyclonal antibodies are engineered specifically for in vitro diagnostic assays to identify biomarkers linked to specific pathologies. Key factors fueling this growth include the rising global incidence of chronic and infectious diseases, which drives the need for precise early detection, as well as the increasing implementation of personalized medicine that relies on accurate patient stratification. Additionally, the aging global population continues to generate strong demand for high-volume diagnostic testing and immunohistochemistry services.

Despite these positive indicators, the industry encounters substantial obstacles due to rigorous regulatory frameworks regarding the validation and commercialization of new diagnostic reagents, which often prolong development schedules. These compliance requirements can hinder the swift introduction of innovative solutions, even when clinical needs are urgent. This demand is highlighted by data from the American Cancer Society, which projects that over two million new cancer cases will be diagnosed in the United States in 2024. This significant disease burden emphasizes the essential need for sophisticated diagnostic tools, even as regulatory complexities persist as a major hurdle to market expansion.

Market Driver

The escalating prevalence of chronic and infectious diseases serves as a major engine for growth in the global diagnostic specialty antibodies market. As the burden of disease intensifies, healthcare infrastructure is increasingly dependent on antibody-based assays for the precise identification and monitoring of pathogens. According to the 'Global Tuberculosis Report 2024' released by the World Health Organization in October 2024, approximately 8.2 million individuals were newly diagnosed with tuberculosis in 2023, marking the highest figure since global tracking commenced. Moreover, the widespread nature of non-communicable diseases requires continuous biomarker monitoring; the International Diabetes Federation reported that approximately 589 million adults globally were living with diabetes in 2024, highlighting the immense scale of chronic conditions necessitating persistent surveillance.

The advancement of personalized medicine and companion diagnostics also plays a pivotal role in driving market expansion. Contemporary therapeutic approaches, especially within oncology, rely heavily on antibody-mediated testing to pinpoint specific biomarkers prior to administering treatment, ensuring that specialty antibodies remain vital for patient stratification. Consequently, major industry participants are experiencing continued growth. For instance, Roche's 'Annual Report 2024', published in January 2025, revealed that their Diagnostics Division sales rose by 4% to CHF 14.3 billion, a performance attributed largely to robust demand for immunodiagnostic products and companion diagnostics. This financial success confirms the indispensable role of high-specificity antibodies in facilitating precision medicine.

Market Challenge

Strict regulatory frameworks controlling the validation and commercialization of new diagnostic reagents present a major obstacle to the growth of the Global Diagnostic Specialty Antibodies Market. Authorities worldwide are implementing increasingly stringent standards for clinical evidence to confirm the sensitivity and specificity of antibodies utilized in in vitro diagnostic (IVD) assays. These compliance mandates require comprehensive data gathering and extended clinical trials, which significantly prolong development timelines and increase capital costs. As a result, manufacturers are frequently forced to redirect vital resources from research and development toward compliance efforts, creating a bottleneck that slows the introduction of novel biomarkers necessary for detecting complex pathologies.

This operational pressure directly inhibits market expansion by deterring product launches in regions defined by complicated regulatory environments. The uncertainty surrounding approval timelines establishes a barrier to entry that impacts both established corporations and emerging biotechnology companies, compelling them to streamline portfolios and discard niche diagnostic applications. Highlighting this reduction in market activity, industry survey data from MedTech Europe in 2024 indicated that the choice of the European Union as the primary region for initial product launches fell by 40 percent among major diagnostic manufacturers due to these regulatory intricacies. Such strategic pivots and delays restrict the accessibility of critical diagnostic tools, ultimately limiting the sector's revenue potential.

Market Trends

The incorporation of Artificial Intelligence into antibody discovery and design is fundamentally transforming the development of diagnostic specialty antibodies by shortening screening durations and enhancing binding affinity. Generative AI models now have the capacity to predict protein structures and engineer novel antibody sequences with high specificity, thereby circumventing traditional, labor-intensive animal immunization methods. This technological evolution facilitates the rapid generation of antibodies against targets previously considered undruggable, significantly speeding up the commercialization of new diagnostic assays. Emphasizing this investment in AI-driven biology, a press release from Business Wire in April 2024 titled 'Xaira Therapeutics Launches to Deliver Transformative Medicines by Advancing and Harnessing AI for Drug Discovery and Development' announced that Xaira Therapeutics debuted with over $1 billion in committed capital to revolutionize antibody and drug discovery through end-to-end AI applications.

Concurrently, a notable transition toward Point-of-Care (POC) antibody-based diagnostic testing is decentralizing the market, shifting testing procedures from centralized laboratories to primary care environments and pharmacies. This trend is fueled by the necessity for immediate clinical decision-making, utilizing rapid lateral flow assays and compact microfluidic devices that employ high-affinity antibodies to identify pathogens or chronic biomarkers within minutes. Consequently, leading diagnostic firms are aggressively acquiring specialized technologies to bolster their decentralized testing capabilities. Confirming this strategic consolidation, Roche announced in July 2024, in 'Roche closes acquisition of LumiraDx's Point of Care technology to expand access to diagnostic testing in primary care', that it had finalized the acquisition of LumiraDx's point-of-care technology for USD 295 million to strengthen its global offerings in decentralized diagnostics.

Key Market Players

• F Hoffmann-La Roche Ltd
• Abcam Limited
• Abbott Laboratories Inc
• Bio-Rad Laboratories Inc
• Agilent Technologies Inc
• Creative Diagnostics
• Thermo Fisher Scientific Inc
• Becton Dickinson & Company
• Merck KGaA
• Sartorius AG

Report Scope

In this report, the Global Diagnostic Specialty Antibodies Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Diagnostic Specialty Antibodies Market, By Antibody

• Monoclonal Antibodies
• Polyclonal Antibodies
• Recombinant Polyclonal Antibodies

Diagnostic Specialty Antibodies Market, By Application

• Dengue Diagnostics
• HIV Diagnostics
• Hepatitis Diagnosis
• Infectious Disease Diagnostics
• Oncology Diagnostics
• Tuberculosis Diagnostics

Diagnostic Specialty Antibodies Market, By End User

• Diagnostic Laboratories
• Hospitals
• Others

Diagnostic Specialty Antibodies Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Diagnostic Specialty Antibodies Market.

Available Customizations:

Global Diagnostic Specialty Antibodies Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Diagnostic Specialty Antibodies Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Antibody (Monoclonal Antibodies, Polyclonal Antibodies, Recombinant Polyclonal Antibodies)
  • 5.2.2. By Application (Dengue Diagnostics, HIV Diagnostics, Hepatitis Diagnosis, Infectious Disease Diagnostics, Oncology Diagnostics, Tuberculosis Diagnostics)
  • 5.2.3. By End User (Diagnostic Laboratories, Hospitals, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Diagnostic Specialty Antibodies Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Antibody
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Diagnostic Specialty Antibodies Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Antibody
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Diagnostic Specialty Antibodies Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Antibody
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Diagnostic Specialty Antibodies Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Antibody
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Diagnostic Specialty Antibodies Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Antibody
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Diagnostic Specialty Antibodies Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Antibody
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. France Diagnostic Specialty Antibodies Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Antibody
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Diagnostic Specialty Antibodies Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Antibody
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Diagnostic Specialty Antibodies Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Antibody
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Diagnostic Specialty Antibodies Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Antibody
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia Pacific Diagnostic Specialty Antibodies Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Antibody
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Diagnostic Specialty Antibodies Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Antibody
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India Diagnostic Specialty Antibodies Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Antibody
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Diagnostic Specialty Antibodies Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Antibody
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Diagnostic Specialty Antibodies Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Antibody
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Diagnostic Specialty Antibodies Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Antibody
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. Middle East & Africa Diagnostic Specialty Antibodies Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Antibody
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Diagnostic Specialty Antibodies Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Antibody
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Diagnostic Specialty Antibodies Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Antibody
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Diagnostic Specialty Antibodies Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Antibody
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. South America Diagnostic Specialty Antibodies Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Antibody
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Diagnostic Specialty Antibodies Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Antibody
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Diagnostic Specialty Antibodies Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Antibody
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Diagnostic Specialty Antibodies Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Antibody
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Diagnostic Specialty Antibodies Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. F Hoffmann-La Roche Ltd
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Abcam Limited
• 15.3. Abbott Laboratories Inc
• 15.4. Bio-Rad Laboratories Inc
• 15.5. Agilent Technologies Inc
• 15.6. Creative Diagnostics
• 15.7. Thermo Fisher Scientific Inc
• 15.8. Becton Dickinson & Company
• 15.9. Merck KGaA
• 15.10. Sartorius AG

16. Strategic Recommendations

17. About Us & Disclaimer